Drug Development (HAV)

Discovery of a Potent Inhibitor of HBV

Published in Hepatitis Weekly, September 30th, 1996

A new drug is more a more potent inhibitor of HBV than 3TC.

Primary human hepatitis B virus (HBV) infections usually resolve within 6 months, but persistent infection occurs in 6-10 percent of cases.

These chronic carriers have a significant risk of developing cirrhosis and/or hepatocellular carcinoma. An effective treatment has yet to be realized, said Drs. Richard Colonno, and Robert Zahler at a presentation to the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting, held in New Orleans, Louisiana, September 15-18, 1996.

A viral encoded protein, called a polymerase, is central to the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1996-09-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry